Guided Therapeutics (GTHP) Convertible Debt (2014 - 2025)
Guided Therapeutics (GTHP) reported Convertible Debt of $35000.0 for Q1 2025, down 96.9% on a YoY basis from $1.1 million in Q1 2024, and up 150.0% sequentially from $14000.0 in Q4 2024.
Guided Therapeutics (GTHP) Convertible Debt (2014 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 12 years of Convertible Debt data on file, last reported at $35000.0 in Q1 2025.
- For the quarter ending Q1 2025, Convertible Debt fell 96.9% year-over-year to $35000.0; the trailing twelve-month figure through Mar 2025 stood at $35000.0 (down 96.9% YoY), and the FY2024 full-year result was $14000.0, changed N/A from the prior year.
- Convertible Debt climbed to $35000.0 in Q1 2025, from $14000.0 in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $1.1 million in Q1 2024 to a low of $14000.0 in Q4 2024.
- A 5-year average of $612750.0 and a median of $803000.0 in 2021 frame the typical range for Convertible Debt.
- Across the five-year window, Convertible Debt surged 978.43% in 2021 and slumped 96.9% in 2025, its largest moves.
- Tracing GTHP's Convertible Debt over 5 years: stood at $820000.0 in 2021, then advanced by 27.56% to $1.0 million in 2022, then dropped by 6.12% to $982000.0 in 2023, then plunged by 98.57% to $14000.0 in 2024, then soared by 150.0% to $35000.0 in 2025.
- Business Quant data shows GTHP's Convertible Debt at $35000.0 in Q1 2025, $14000.0 in Q4 2024, and $162000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 14,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 1.13 Mn |
| Mar 31, 2023 | 982,000.00 |
| Dec 31, 2022 | 1.05 Mn |
| Sep 30, 2022 | 1.02 Mn |
| Jun 30, 2022 | 786,000.00 |
| Mar 31, 2022 | 161,000.00 |
| Dec 31, 2021 | 820,000.00 |
| Mar 31, 2021 | 1.10 Mn |
| Dec 31, 2020 | 161,000.00 |
| Sep 30, 2020 | 622,000.00 |
| Jun 30, 2020 | 525,000.00 |
| Mar 31, 2020 | 102,000.00 |
| Dec 31, 2019 | 512.72 Mn |
| Sep 30, 2019 | 65,000.00 |
| Jun 30, 2019 | 520,000.00 |
| Mar 31, 2019 | 445,000.00 |